Dr. van Deventer was trained as an internist and board-certified gastroenterologist, received a doctorate of philosophy from the University of Amsterdam, worked as a scientist at Rockefeller University and became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam in 1995.
In 1998, he co-founded Amsterdam Molecular Therapeutics (AMT; currently Uniqure), a gene therapy company that develops AAV-based gene therapy products. From 2001 until 2004, he chaired the Department of Gastroenterology and Hepatology at the Academic Medical Center in Amsterdam. Dr. van Deventer has had a critical role in the development of the first commercial monoclonal antibody (Remicade) and the first gene therapy to be granted market authorization in the Western world (Glybera). He currently is a Managing Partner at Forbion Capital Partners and Professor of Translational Gastroenterology Leiden University Medical Center. He is a member of the Boards of Argos Therapeutics (Durham, USA), Uniqure (Amsterdam, The Netherlands), Hookipa (Vienna, Austria), Staten Biotechnology (Naarden, The Netherlands) and enGene (Montreal, Canada).
Dr. Ross Feldman is Medical Director, Cardiac Sciences Program for the Winnipeg Regional Health Authority, in addition he is also Professor of Medicine at the University of Manitoba.
He was just recently the Chair of Medicine at Memorial University of Newfoundland, St. John’s Newfoundland & Labrador, Canada. He is the author of more than 200 original manuscripts, reviews and book chapters. His clinical research program centers on the development of new approaches to the management of hypertension and specifically the development of innovative strategies to improve blood pressure control.
A major focus of his efforts has been in the prevention and control of hypertension in Canada and specifically in the knowledge translation of optimal treatment approaches for hypertension management. Among past leadership positions, Dr. Feldman served as the first Chair of the Steering Committee of the Canadian Hypertension Education Program, the organization that since 1999 has produced, disseminated and implemented annually updated guidelines for management of hypertension. As well, he served as President of the Canadian Hypertension Society. He was also the founding President of Hypertension Canada- leading the process of integrating the efforts of the Canadian Hypertension Society, Canadian Hypertension Education Program and Blood Pressure Canada.
He has received a number of awards and scholarships in recognition of his contributions in research, teaching and for his efforts in the prevention and control of hypertension in Canada. These include the George Morris Piersol Research and Teaching Scholarship from the American College of Physicians, a Career Investigator Award from the Heart and Stroke Foundation of Ontario, the Burroughs-Wellcome Clinical Pharmacology Award and the Senior Investigator Award from the Canadian Society for Clinical Pharmacology as well as the Distinguished Service/Research Award of the Canadian Hypertension Society. He also the recipient of the George Fodor Award from Hypertension Canada for outstanding contributions to the prevention and control of hypertension.
Paul Knill earned his law degree from Western University, and is a graduate of the Institute of Corporate Directors, Rotman School of Management.
Paul served as Managing Partner at the Canadian Law Firm, Siskinds LLP, during a period of significant expansion and change. His leadership encouraged innovative gathering and sharing of intellectual capital among business unit members. Paul went on to serve as an adjunct professor at Western University law school, and he currently contributes his corporate governance expertise by serving on the boards of a diverse number of Corporations.